UBS Group
MBX

UBS Group’s MBX Biosciences MBX Stock Holding History

UBS Group’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4M Buy
346,914
+65,702
+23% +$2.23M ﹤0.01% 3304
2025
Q4 		$8.87M Buy
281,212
+220,487
+363% +$5.35M ﹤0.01% 3419
2025
Q3 		$1.06M Buy
60,725
+29,758
+96% +$398K ﹤0.01% 5526
2025
Q2 		$353K Buy
30,967
+3,468
+13% +$35.3K ﹤0.01% 6308
2025
Q1 		$203K Sell
27,499
-18,402
-40% -$195K ﹤0.01% 6547
2024
Q4 		$846K Buy
+45,901
New +$978K ﹤0.01% 5442

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

UBS Group's MBX Position: Q1 2026 in Review

UBS Group increased its MBX Biosciences (MBX) stake by 23% in Q1 2026, buying an estimated $2.23M and bringing the position to 346,914 shares worth $10.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3304.

UBS Group first reported a position in MBX in Q4 2024 and has held it in 6 quarters since. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

  • UBS Group held 346,914 shares of MBX Biosciences worth $10.4M as of Q1 2026.
  • UBS Group bought 65,702 MBX Biosciences shares in Q1 2026, an estimated $2.23M.
  • MBX Biosciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3304 holding.
  • UBS Group first reported a position in MBX Biosciences in Q4 2024 and has held it in 6 quarters since.
  • 157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.